• Patients with either monoclonal gammopathy of unknown significance age \>= 18 years old.

⁃ Both criteria must be met:

∙ Serum monoclonal protein \< 3 g/dL or urinary monoclonal protein \< 500 mg per 24 hours and clonal bone marrow plasma cells \< 10%

‣ Absence of myeloma defining events or amyloidosis

• OR Patients with smoldering multiple myeloma age \>= 18 years old.

⁃ Both criteria must be met:

∙ Serum monoclonal protein \>= 3 g/dL or urinary monoclonal protein \>= 500 mg per 24 hours and/or clonal bone marrow plasma cells 10-60%

‣ Absence of myeloma defining events or amyloidosis

• Patients must be enrolled in clinical trials for SMM or MGUS at MD Anderson Cancer Center, including protocols PA15-0575 (NCT02726750) (Prospective observational study of clinical and genomic predictors of progression to myeloma in asymptomatic monoclonal gammopathies); 2015-0148 (Phase II single arm trial of Isatuximab in patients with intermediate and high risk smoldering multiple myeloma); and 2015-0371 (NCT02603887) (Pilot single arm, single center, open label trial of Pembrolizumab in patients with intermediate and high risk smoldering multiple myeloma) and any future clinical trials for MGUS and/or SMM that open at MD Anderson Cancer Center.

• Only patients who are English or Spanish speaking are eligible.